Tarsus Pharmaceuticals Inc
TARS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.5B
Close$
$-40.00
154.6% downside
Current Fair Value
154.6% downsideOvervalued by 154.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.50 Billion |
|---|---|
| Enterprise Value | $3.30 Billion |
| Earnings per Share | $-1.59 |
| Beta | 0.54 |
| Outstanding Shares | 43,393,643 |
Return
| Return on Equity | -13.40% |
|---|---|
| Return on Assets | -7.60% |
| Return on Invested Capital | -8.83% |
Valuation & Multiples
| P/E Ratio | -68.67 |
|---|---|
| PEG | 780.74 |
| Price to Sales | 5.64 |
| Price to Book Ratio | 10.47 |
| Enterprise Value to Revenue | 5.44 |
| Enterprise Value to EBIT | -85.81 |
| Enterprise Value to Net Income | -71 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.19
Consensus analyst estimateRevenue Estimate
$169.65 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-1.46
Consensus analyst estimateRevenue Estimate
$187.83 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 97.11% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.29%▼ 106.54% |
|---|---|
| Total Invested | $112.21M▼ 96.26% |
| Investors Holding | 46▼ 224.00% |
About Tarsus Pharmaceuticals Inc
20 employees
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address a num...